Anugerah 88 Logo
$5.71+0.09|(+1.60%)
52W H: 7.1952W L: 1Beta: -0.99

About AN2 Therapeutics Inc

Frequently Asked Questions

What is the 52-week range for ANTX?

The 52-week high is $7.19 and the 52-week low is $1.

What is the P/E ratio for ANTX?

The P/E ratio data is currently unavailable.

What is the dividend yield for ANTX?

This company does not currently pay a dividend or the data is unavailable.

What is the Return on Equity (ROE)?

The trailing twelve months (TTM) Return on Equity is -53.52%.

What is the Net Profit Margin?

Net Margin data is currently unavailable.

What is the Price to Book (P/B) Ratio?

The annual Price to Book ratio stands at 0.59.

Analyst Recommendation Trends

Wall Street analyst consensus for ANTX over the last few months:

2026-09-01
Buy: 3
S.Buy: 4
Hold: 1
Sell: 0
2026-08-01
Buy: 3
S.Buy: 4
Hold: 1
Sell: 0
2026-07-01
Buy: 3
S.Buy: 3
Hold: 1
Sell: 0
2026-06-01
Buy: 3
S.Buy: 3
Hold: 1
Sell: 0

Latest ANTX News

GSK (LSE:GSK) The Latest Update Raises A Bigger Question

Fresh funding from the Gates Foundation for AN2 Therapeutics’ tuberculosis collaboration with GSK (LSE:GSK) has put the pharma group’s boron based LeuRS inhibitor program back in focus for investors. The GSK share price has softened in the very short term, with a 1-day share price return of a 0.22% decline and a 7-day share price return of a 2.62% decline, even as fresh R&D headlines such as the Gates backed TB work and recent conference appearances keep the pipeline in view. Yet momentum...

Yahoo9/30/2026

AN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSK

MENLO PARK, Calif., September 28, 2026--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage pharmaceutical company focused on the discovery and development of small molecule therapeutics derived from its boron chemistry platform, today announced that the Gates Foundation has awarded an extension of funding to support AN2 Therapeutics' research activities under its ongoing tuberculosis (TB) research collaboration with GSK focused on the development of boron-based leucyl-tRNA synthetase (LeuRS

Yahoo9/28/2026

AN2 Therapeutics: A Failed Drug Could Become A Major Value Driver

AN2 Therapeutics looks attractive with a risk-adjusted base-case valuation of approximately $12 per share. Read why I rate ANTX stock a Buy now.

SeekingAlpha9/22/2026

AN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4)

MENLO PARK, Calif., September 16, 2026--AN2 Therapeutics, Inc. (NASDAQ: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced it granted inducement equity awards to Cameron Trenor, M.D., the Company’s newly-appointed Chief Medical Officer.

Yahoo9/16/2026

Related Stocks (Peers)

Companies operating in similar sectors to ANTX:

EYPTPLTH.CNELTPSIGAANTXSDEVORMPDERMJUSH.CNGRIN.CNLLY

Recent Insider Transactions

DateNameShares ChangedPriceValue
2026-09-15Trenor Cameron C. III+233,333--
2026-09-15Trenor Cameron C. III+116,667--
2026-09-09Readnour Robin Shane-585$6.0243$3,524
2026-09-09Readnour Robin Shane-523$6.0243$3,151
2026-09-08Readnour Robin Shane-5,294$6.0183$31,861
2026-09-08Readnour Robin Shane-4,725$6.0183$28,436
2026-09-03Readnour Robin Shane-3,223$6.0698$19,563
2026-09-03Readnour Robin Shane-2,877$6.0698$17,463
2026-09-01Williams Sarah Joanne-272$5.53$1,504
2026-09-01FitzPatrick Margaret M+2,098$5.53$11,602
2026-08-17Readnour Robin Shane-18,706$6.0082$112,389
2026-08-17Readnour Robin Shane-16,696$6.0082$100,313
2026-08-14Zakrzewski Joseph S-405,880--
2026-07-10Aziz Kabeer+2,852--
2026-07-10Marks Gilbert Lynn+2,789--
2026-07-10Martin Patricia A.+766--
2026-07-08Eizen Joshua M-5,945$4.172$24,803
2026-05-29Williams Sarah Joanne-265$4.43$1,174
2026-04-10Aziz Kabeer+3,775--
2026-04-10Marks Gilbert Lynn+3,775--
2026-04-10Martin Patricia A.+1,192--
2026-03-19Day Lucy-82,300--
2026-03-19Day Lucy+82,300--
2026-03-19Day Lucy-66,000--
2026-03-19Day Lucy+66,000--
2026-03-19Day Lucy-73,665--
2026-03-19Day Lucy+73,665--
2026-03-19Marks Gilbert Lynn-23,742--
2026-03-19Marks Gilbert Lynn+23,742--
2026-03-19Marks Gilbert Lynn-10,362--
2026-03-19Marks Gilbert Lynn+10,362--
2026-03-19Marks Gilbert Lynn-10,665--
2026-03-19Marks Gilbert Lynn+10,665--
2026-03-19Aziz Kabeer-23,742--
2026-03-19Aziz Kabeer+23,742--
2026-03-19Aziz Kabeer-20,724--
2026-03-19Aziz Kabeer+20,724--
2026-03-19Martin Patricia A.-23,742--
2026-03-19Martin Patricia A.+23,742--
2026-03-19Martin Patricia A.-10,362--
2026-03-19Martin Patricia A.+10,362--
2026-03-19Martin Patricia A.-24,999--
2026-03-19Martin Patricia A.+24,999--
2026-03-19Eizen Joshua M-50,150--
2026-03-19Eizen Joshua M+50,150--
2026-03-19Eizen Joshua M-92,000--
2026-03-19Eizen Joshua M+92,000--
2026-03-19Readnour Robin Shane-23,742--
2026-03-19Readnour Robin Shane+23,742--
2026-03-19Readnour Robin Shane-20,724--
2026-03-19Readnour Robin Shane+20,724--
2026-03-19Easom Eric-267,650--
2026-03-19Easom Eric+267,650--
2026-03-19Easom Eric-225,000--
2026-03-19Easom Eric+225,000--
2026-03-19Easom Eric-249,999--
2026-03-19Easom Eric+249,999--
2026-03-19FitzPatrick Margaret M-23,742--
2026-03-19FitzPatrick Margaret M+23,742--
2026-03-19FitzPatrick Margaret M-10,362--
2026-03-19FitzPatrick Margaret M+10,362--
2026-03-19FitzPatrick Margaret M-11,463--
2026-03-19FitzPatrick Margaret M+11,463--
2026-03-19Chanda Sanjay-41,665--
2026-03-19Chanda Sanjay+41,665--
2026-03-19Chanda Sanjay-57,950--
2026-03-19Chanda Sanjay+57,950--
2026-03-19Chanda Sanjay-66,000--
2026-03-19Chanda Sanjay+66,000--
2026-03-19Wong Stephanie-23,742--
2026-03-19Wong Stephanie+23,742--
2026-03-19Wong Stephanie-10,362--
2026-03-19Wong Stephanie+10,362--
2026-03-19Wong Stephanie-24,999--
2026-03-19Wong Stephanie+24,999--
2026-03-19Spigelman Melvin K-23,742--
2026-03-19Spigelman Melvin K+23,742--
2026-03-19Spigelman Melvin K-10,362--
2026-03-19Spigelman Melvin K+10,362--
2026-03-19Spigelman Melvin K-16,941--
2026-03-19Spigelman Melvin K+16,941--
2026-03-19Zakrzewski Joseph S-23,742--
2026-03-19Zakrzewski Joseph S+23,742--
2026-03-19Zakrzewski Joseph S-10,362--
2026-03-19Zakrzewski Joseph S+10,362--
2026-03-19Zakrzewski Joseph S-99,999--
2026-03-19Zakrzewski Joseph S+99,999--
2026-03-03Williams Sarah Joanne-327$1.06$347
2026-02-20Eizen Joshua M+100,000--
2026-02-20Eizen Joshua M+50,000--
2026-02-20Day Lucy-77,000--
2026-02-20Day Lucy+38,000--
2026-02-20Williams Sarah Joanne+48,375--
2026-02-20Easom Eric+224,500--
2026-02-20Easom Eric+112,250--
2026-02-20Marks Gilbert Lynn+20,400--
2026-02-20Readnour Robin Shane+20,400--
2026-02-20Martin Patricia A.+20,400--
2026-02-20Aziz Kabeer+20,400--
2026-02-20FitzPatrick Margaret M+20,400--
2026-02-20Chanda Sanjay+77,000--
2026-02-20Chanda Sanjay+38,000--
2026-02-20Wong Stephanie+20,400--
2026-02-20Spigelman Melvin K+20,400--
2026-02-20Zakrzewski Joseph S+20,400--
2026-01-12Aziz Kabeer+11,560--
2026-01-12Martin Patricia A.+3,650--
2026-01-12Marks Gilbert Lynn+11,560--
2026-01-06Day Lucy-5,512$1.012$5,578
2026-01-06Prior Stephen David-2,858$1.012$2,892
2026-01-06Eizen Joshua M-6,931$1.012$7,014
2026-01-06Chanda Sanjay-5,956$1.012$6,027
2026-01-05Day Lucy-3,295$1.003$3,305
2026-01-05Prior Stephen David-3,604$1.003$3,615
2026-01-05Eizen Joshua M-17,923$1.0014$17,948
2026-01-05Chanda Sanjay-3,295$1.003$3,305
2025-11-04Eizen Joshua M-2,819$1.14$3,214
2025-11-04Prior Stephen David-765$1.14$872
2025-10-10Marks Gilbert Lynn+10,367--
2025-10-10Aziz Kabeer+10,367--
2025-10-10Martin Patricia A.+3,274--